Vol.

No.

March 17, 2017Mar 17, 2017

Free

DOWNLOAD THE PDF

Trump's proposed 2018 budget launches a surprise attack on NIH

Cover Story

Free

Trump's proposed 2018 budget launches a surprise attack on NIH

By Paul Goldberg and Matthew Bin Han Ong

FDA may have escaped the devastating cuts in President Trump's first budget proposal, while NIH ended up taking the brunt of its fury.

Conversation with The Cancer Letter Free

John Porter: If you want to make America great, you don't take America's worldwide scientific lead and cut it

By Paul Goldberg

Conversation with The Cancer Letter Free

Nancy Davidson: This is the time for investment, not for retreat

By Paul Goldberg

Conversation with The Cancer Letter Free

Ellen Sigal: This is not a grasstops issue anymore, this is really grassroots

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

Blase Polite: This was put together by folks who have no sense of how research is done

By Matthew Bin Han Ong

Conversation with The Cancer Letter Free

Patricia Goldsmith: This is the “Moonstab,” or, maybe, the “Moonshaft”

By Matthew Bin Han Ong

Free

“Duplicity” at NIH? White House spokesman Sean Spicer says the cut isn't really a cut

Free

Beth Caldwell: People like me will die because of these cuts

Free

White House “vision” would cripple NIH

In Brief

Marshall Hicks named interim president of MD Anderson Cancer Center

Stupp named associate director, strategic initiatives at Lurie Cancer Center

City of Hope vice provost to focus on faculty growth initiatives

Nichols named LLS chief medical officer

Penson named chair of Science & Quality Council at American Urological Association

NCI selects ATCC to provide end-to-end cancer epidemiology services

ILO delays vote on whether to cut ties with tobacco industry

Drugs & Targets

Kisqali gets FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

Keytruda gets accelerated approval for classical Hodgkin lymphoma

FDA extends Keytruda PDUFA date for microsatellite instability-high cancer

Mylan announces settlement, license deals with Genentech and Roche on Herceptin

Oncoceutics expands DRD2 research collaborations with NIH

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 44 - November 22, 2024

Trump's proposed 2018 budget launches a surprise attack on NIH

John Porter: If you want to make America great, you don't take America's worldwide scientific lead and cut it

Nancy Davidson: This is the time for investment, not for retreat

Ellen Sigal: This is not a grasstops issue anymore, this is really grassroots

Blase Polite: This was put together by folks who have no sense of how research is done

Patricia Goldsmith: This is the “Moonstab,” or, maybe, the “Moonshaft”

“Duplicity” at NIH? White House spokesman Sean Spicer says the cut isn't really a cut

Beth Caldwell: People like me will die because of these cuts

White House “vision” would cripple NIH

In Brief

Marshall Hicks named interim president of MD Anderson Cancer Center

Stupp named associate director, strategic initiatives at Lurie Cancer Center

City of Hope vice provost to focus on faculty growth initiatives

Nichols named LLS chief medical officer

Penson named chair of Science & Quality Council at American Urological Association

NCI selects ATCC to provide end-to-end cancer epidemiology services

ILO delays vote on whether to cut ties with tobacco industry

Drugs & Targets

Kisqali gets FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

Keytruda gets accelerated approval for classical Hodgkin lymphoma

FDA extends Keytruda PDUFA date for microsatellite instability-high cancer

Mylan announces settlement, license deals with Genentech and Roche on Herceptin

Oncoceutics expands DRD2 research collaborations with NIH

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login